AbbVie's update on COVID-19

AbbVie's coronavirus response

As COVID-19 continues to have an increased impact on our communities, we want you to know we are here to help.  AbbVie is focused on the health and safety of employees, health care professionals (HCPs) and patients.

We are collaborating with select health authorities and institutions globally on clinical research related to COVID-19. AbbVie is supporting clinical studies and basic research, working closely with European health authorities and the U.S. Food and Drug Administration, Centers for Disease Control and Prevention, National Institutes of Health and Biomedical Advanced Research and Development Authority to coordinate on these efforts.

Learn more about our efforts below: 

We are continuing to closely monitor manufacturing and supply chain resources around the world to help ensure our patients continue to receive their medicines. We do not anticipate any disruption to our medicine supply for patients as a result of COVID-19.

Learn more.

 

We understand your need to know more about the coronavirus. If you are on an AbbVie treatment, please speak with your doctor regarding any questions you may have. Your doctor can provide medical advice to address your individual needs.
 

Patients enrolled in myAbbVie Assist or seeking assistance

We do not expect service interruptions for patients who receive their medication through myAbbVie Assist, our patient assistance program. If you are unable to pay for your AbbVie medication due to COVID-19 circumstances, click to learn more about the myAbbVie assist program.

AbbVie is donating $25 million to help support underserved communities and healthcare systems working to address the impact of the COVID-19 global pandemic. AbbVie’s partners are:

  • International Medical Corps to help create capacity to treat patients at overburdened hospitals. AbbVie’s donation will support the creation and operation of mobile field hospitals in the United States that will provide capacity and create improved patient flow options as hospitals work to keep COVID-19 patients separated from other patients.
  • Direct Relief to help meet healthcare system needs in the hardest hit countries. This support will enable the procurement and delivery of oxygen concentrators, ventilators and personal protective equipment to healthcare systems and prioritize countries with high infection rates, beginning with Italy, the UK, France and Spain.
  • Feeding America to protect the most vulnerable, including the elderly, by enabling access to food and essential household supplies with minimal contact. Feeding America has created a new model of home delivery and drive-through service.

Included in the $25 million is a reserve of $5 million for a new AbbVie COVID-19 Community Resilience Fund. The Fund will provide up to $1 million in financial support to organizations strengthening community resilience in under-resourced areas impacted by COVID-19.

If you are a registered healthcare provider with questions about COVID-19 and AbbVie medications or adverse event reporting, please visit AbbVie’s medical information website, www.abbviemedinfo.com.

Employees impacted by the coronavirus

If you are an employee that is being impacted by the COVID-19 pandemic and need assistance, the AbbVie Employee Assistance Fund (AEAF) may be able to help. 
Click here to apply and for more information.

 

Protecting our employees

AbbVie is focused on ensuring the safety of our employees while we continue to make the vital medicines our patients depend on.

AbbVie has taken the following steps to protect the health of our employees:

  • A significant number of our employees who have jobs that can be done remotely are now working from home.
  • For those people who need to be at an AbbVie facility to do their job, we’ve taken aggressive steps to limit exposure risk and keep our worksites as safe as possible.
  • We support social distancing at all facilities where possible and encourage all employees to practice recommended safety measures.
  • Enacted strict travel restrictions in accordance with government guidance.

We will continue to closely monitor this evolving situation during this unprecedented global health crisis. 

AbbVie is constantly monitoring and taking precautions to protect the safety of our study participants, clinical trial site staff and our employees. We will continue to evaluate any local support our study participants may require to maintain their safe involvement in our clinical trials.

AbbVie Medical Information for healthcare providers
www.abbviemedinfo.com

Centers for Disease Control Coronavirus disease 2019 (COVID-19)
CDC website

World Health Organization Coronavirus disease (COVID-19) webpage
WHO website

AbbVie Media Relations
Contact us